Selective estrogen receptor modulators: Clinical spectrum

Endocrine Reviews

Volumn 20, Issue 3, 1999, Pages 418-434

  Cosman, F ^a   Lindsay, R ^a  

^a HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; DROLOXIFENE; ESTROGEN; FULVESTRANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IDOXIFENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE MASS; BONE METABOLISM; BREAST CANCER; CANCER PREVENTION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; ESTROGEN THERAPY; EYE DISEASE; FEMALE GENITAL SYSTEM; FEMALE INFERTILITY; FRACTURE; HUMAN; LIPOPROTEIN BLOOD LEVEL; METASTASIS; MOOD; NEUROENDOCRINE SYSTEM; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VASCULAR DISEASE;

EID: 0033305454     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.20.3.418     Document Type: Review

References (185)

1. Overview of estrogen replacement therapy: A historical perspective
2. Some reflections and hypotheses on the pathophysiology of female urinary incontinence
3. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group
4. Prevention of spinal osteoporosis in oophorectomised women
5. Treatment of postmenopausal osteoporosis with transdermal estrogen
6. Estrogen replacement therapy and cardiovascular protection: Lipid mechanisms are the tip of an iceberg
7. The epidemiology of estrogen replacement therapy and Alzheimer's disease
8. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
9. Does estrogen replacement therapy protect against Alzheimer's disease?
10. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature
11. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
12. Anticipating HERS: Questions from the heart and estrogen/progestin replacement study
13. Postmenopausal estrogen and prevention bias
14. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy
15. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer
16. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventive health benefits?
17. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in post menopausal women
18. Combined continuous hormone replacement therapy: A critical review
19. Risk of venous thromboembolism in users of hormone replacement therapy
20. Prospective study of exogenous hormones and risk of pulmonary embolism in women
21. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
22. Clomiphene citrate in disseminated mammary carcinoma
23. Clinical trial of clomiphene in advanced breast cancer
24. The agonistic-antagonistic properties of clomiphene: A review
25. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31000 recur rences and 24000 deaths among 75000 women
26. Tamoxifen for early breast cancer: An overview of the randomised trials
27. Drug therapy. Tamoxifen in the treatment of breast cancer
28. Treatment of breast cancer
29. Five vs. more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
30. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
31. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
32. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV
33. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C
34. Adjuvant CMFVP vs. tamoxifen vs. concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study
35. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institue of Canada Institute of Canada Clinical Trials Group
36. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
37. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
38. Tamoxifen (T) vs. cyclophosphamide, Adriamycin® and 5-FU plus either concurrent or sequential tamoxifen in postmenopausal receptor (+) note (+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100)
39. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival
40. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
41. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
42. Randomized trial of bilateral oophorectomy vs. tamoxifen in premenopausal women with metastic breast cancer
43. Tamoxifen rechallenge: Response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer
44. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study
45. Toremifene, a new antiestrogenic compound in the treatment of advanced breast cancer. Phase II study
46. Phase II clinical study of toremifene in patients with metastatic breast cancer
47. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase-II multicenter Finnish-Latvian cooperative study
48. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastic breast cancer
49. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study
50. European early phase II dose finding study of droloxifene in advanced breast cancer
51. Droloxifene - A new anti-estrogen. A phase II study in advanced breast cancer
52. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
53. Phase I trial of droloxifene in patients with metastatic breast cancer
54. Phase II evaluation of Ly156758 in metastatic breast cancer
55. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
56. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
57. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
58. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
59. Commentary - Is tamoxifen effective in prevention of breast cancer?
60. Ovarian tumors in a cohort of infertile women
61. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case control studies. II. Invasive epithelial ovarian cancers in white women
62. Fertility drugs and ovarian cancer: Red alert or red herring?
63. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women
64. Ovarian cysts in premenopausal tamoxifen-treated women with breast cancer
65. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth
66. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
67. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers
68. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
69. Tamoxifen and the uterus and endometrium
70. Tamoxifen and the uterus and endometrium
71. Tamoxifen
72. Bone histomorphometric results of a 2 year randomized, placebo controlled trial of raloxifene in postmenopausal women
73. Tamoxifen and the uterus
74. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
75. Tamoxifen treatment and its consequences
76. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer
77. Use of tamoxifen for breast cancer: Twenty-eight years later
78. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial
79. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer
80. Endometriosis and tamoxifen therapy
81. The effect of tamoxifen on the endometrium
82. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer
83. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients
84. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
85. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
86. A controlled trial of raloxifene (LY139481) HC1: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
87. Tamoxifen and partial oestrogen agonism in postmenopausal women
88. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles
89. Clinical uses of antiestrogens
90. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
91. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent
92. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen
93. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin anti-thrombin III
94. Clinical aspects and developments of antioestrogen therapy: A review of the endocrine effects of tamoxifen in animals and man
95. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients
96. Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients
97. Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer
98. Hormonal and receptor status in postmenopausal women with endometrial carcinoma before and after treatment with tamoxifen
99. Endocrine effects of tamoxifen in postmenopausal breast cancer patients
100. Influence of toremifene on the endocrine regulation in breast cancer patients
101. Tamoxifen: A review of its pharmacological properties and therapeutic use in the treatment of breast cancer
102. Tamoxifen in advanced breast cancer
103. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma
104. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
105. Symptoms associated with tamoxifen treatment in postmenopausal women
106. Coronary heart disease mortality and adjuvant tamoxifen therapy
107. 3-[4-(1,2-Diphenylbut-1-enyl)phenylacrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats
108. Clomiphene protects against osteoporosis in the mature ovariectomized rat
109. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats
110. Idoxifene increases bone mineral density on osteopenic postmenopausal women
111. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
112. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women
113. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
114. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women
115. Effect of long term tamoxifen treatment on bone turnover in women with breast cancer
116. Effect of long term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer
117. The short term effects of tamoxifen on bone turnover in older women
118. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer
119. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years
120. Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women
121. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party
122. Bone mineral content of women receiving tamoxifen for mastalgia
123. Effects of tamoxifen on spinal bone density in women with breast cancer
124. Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study
125. Tamoxifen protects against steroid-induced bone loss
126. Effect of tamoxifen on lumbar spine bone mineral density in post menopausal women after 5 years
127. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
128. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen
129. Treatment of established post-menopausal osteoporosis with raloxifene: A randomized trial
130. Raloxifene and estrogen: Comparative bone remodeling kinetics
131. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
132. Raloxifene reduces the risk of incident vertebral fractures: 24-Month interim analyses. Proceedings of the European Congress on Osteoporosis
133. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels
134. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
135. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
136. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
137. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
138. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women
139. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
140. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to menopausal status
141. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: A mechanism accounting for the cardioprotective action of tamoxifen?
142. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women
143. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
144. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels
145. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III
146. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy
147. Effect of tamoxifen on measurements of hemostasis in healthy women
148. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis
149. Effects of tamoxifen on blood coagulation
150. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
151. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
152. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen
153. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels
154. Systemic therapty in node-negative patients: Updated findings from NSABP clinical trials
155. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
156. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
157. Effects of raloxifene in postmenopausal women
158. Symptoms associated with tamoxifen treatment in postmenopausal women
159. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women
160. Reversible ocular toxicity related to tamoxifen therapy
161. Tamoxifen retinopathy
162. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen
163. Tamoxifen retin opathy: A case report
164. Ocular toxicity of tamoxifen
165. Tamoxifen-induced ocular toxicity
166. Tamoxifen retinopathy: A rare but serious complication
167. A controlled study of the ocular effects of tamoxifen in conventional dosate in the treatment of breast carcinoma
168. Clear evidence that long-term, low dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients
169. A case report. Low dose tamoxifen retinopathy
170. Long-term tamoxifen citrate use and potential ocular toxicity
171. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat
172. Major differences in the hepato-carcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1:CD(BR) rats
173. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
174. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen